10.3389/fpsyg.2018.02065.s002 Sheng Wei Sheng Wei Peng Sun Peng Sun Yinghui Guo Yinghui Guo Jingxuan Chen Jingxuan Chen Jieqiong Wang Jieqiong Wang Chunhong Song Chunhong Song Zifa Li Zifa Li Ling Xue Ling Xue Mingqi Qiao Mingqi Qiao Data_Sheet_2_Gene Expression in the Hippocampus in a Rat Model of Premenstrual Dysphoric Disorder After Treatment With Baixiangdan Capsules.ZIP Frontiers 2018 premenstrual dysphoric disorder gene chip Baixiangdan differentially expressed genes gene ontology KEGG signal pathways traditional Chinese medicine 2018-11-13 04:29:07 Dataset https://frontiersin.figshare.com/articles/dataset/Data_Sheet_2_Gene_Expression_in_the_Hippocampus_in_a_Rat_Model_of_Premenstrual_Dysphoric_Disorder_After_Treatment_With_Baixiangdan_Capsules_ZIP/7331552 <p>Objective: To explore the targets, signal regulatory networks and mechanisms involved in Baixiangdan (BXD) capsule regulation of premenstrual dysphoric disorder (PMDD) at the gene transcription level, since the etiology and pathogenesis of PMDD are not well understood.</p><p>Methods: The PMDD rat model was prepared using the resident-intruder paradigm. The rats were tested for aggressive behavior, and those with scores in the lowest 30% were used as controls, while rats with scores in the highest 30% were divided into a PMDD model group, BXD administration group and fluoxetine administration group, which were evaluated with open-field tests and aggressive behavior tests. We also analyzed gene expression profiles in the hippocampus for each group, and verified differential expression of genes by real-time PCR.</p><p>Results: Before and after BXD or fluoxetine administration, scores in the open-field test exhibited no significant differences. The aggressive behavior of the PMDD model rats was improved to a degree after administration of both substances. Gene chip data indicated that 715 genes were differentially expressed in the control and BXD groups. Other group-to-group comparisons exhibited smaller numbers of differentially expressed genes. The effective targets of both drugs included the Htr2c, Cdh3, Serpinb1a, Ace, Trpv4, Cacna1a, Mapk13, Mapk8, Cyp2c13, and Htr1a genes. The results of real-time PCR tests were in accordance with the gene chip data. Based on the target genes and signaling pathway network analysis, we have elaborated the impact and likely mechanism of BXD in treating PMDD and premenstrual irritability.</p><p>Conclusion: Our work contributes to the understanding of PMDD pathogenesis and the mechanisms of BXD treatment. We speculate that the differentially expressed genes could participate in neuroactive ligand-receptor interactions, mitogen-activated protein kinase, calcium, and gamma-aminobutyric acid signal transduction.</p>